NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Atsena Therapeutics

Atsena Therapeutics

Private
Durham, North CarolinaHealthcare & Life Scienceshttps://atsenatx.com/

Last Round

Series C

Apr 2, 2025

Est. Valuation

$340M

Total Funding Raised

$237.65M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Atsena Therapeutics is a biotechnology company that develops ocular gene therapies aimed at reversing or preventing blindness caused by inherited retinal diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

gene therapyinherited retinal diseasesX-linked retinoschisisXLRSadeno-associated virusAAVStargardt diseasebiotechclinical trialsretinal gene therapyorphan drugbiopharmaceuticaldual-vector gene therapycapsid engineeringrare disease biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Atsena Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Atsena Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Atsena Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CApr 2, 2025
Series BOct 2, 2023
Series ADec 16, 2020
Series 1Apr 1, 2020

Key People

Founding team and executive leadership

Shannon Boye

Founder and Chief Scientific Officer, Founder and Director

Founding Team

Atsena Therapeutics Investors

Notable investors and investment history

Atsena Therapeutics investors
InvestorRounds
Bain Capital Life SciencesSeries C
Lightstone VenturesSeries A, Series C, Series B
Hatteras Venture PartnersSeries A, Series C, Series B, Series 1
Osage University PartnersSeries A, Series C, Series B, Series 1
The Manning Family FoundationSeries A, Series B, Series C
PBM Capital GroupSeries 1
AbingworthSeries A, Series C, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 1, 2026

    Grew 15% QoQ, from 39 to 45 employees.

  • May 17, 2026

    Monthly visitors grew 115% MoM, reaching 18.9K.

Atsena Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Atsena Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Atsena Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersDurham, North Carolina
Employee Range48
Year Founded2019
Last FundingApr 2, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.